Foundation stone laid for Laboratoire Unither Amiens new building


Foundation stone laid for Laboratoire Unither Amiens new building


As part of the Foundation Stone Laying Ceremony for the new building designed to produce vaccines, Unither Amiens hosted Alain Gest, President of Amiens Metropole, Sophie Remont, Director of Expertise and Programs at Bpifrance, and Jean-Christophe Loric, Regional Councilor for Hauts-de-France.


Unither Pharmaceuticals President Eric Goupil reaffirmed the Group’s commitment to making healthcare solutions that improve and simplify patients’ lives accessible to as many people as possible, thanks to Euroject®, an innovation based on Blow-Fill-Seal (BFS) technology for the unitary injection of vaccines and biological products.


The 6,000-square-meter extension to Laboratoire Unither in Amiens will house vaccines and, more generally, biological products requiring BSL 1 and 2. The project began in 2023 and will be completed in 2025. Three filling lines will be installed, and two more will be added, resulting in the production of over 1 billion doses a year. This project represents a total investment of €95,000,000 and has received a financial contribution from the French government as part of the Future Investment Program.



Euroject® building foundation stone laying at Laboratoire Unither Amiens  


About Laboratoire Unither Amiens

Laboratoire Unither Amiens was the first to specialize in Blow-Fill-Seal technology. It was founded in 1993 by Patrick Colin. Thanks to its extensive experience, the site has become a leader in the manufacture of healthcare products for rhinology, asthma treatment, ophthalmology and antisepsis. Capable of manufacturing more than 1.6 billion doses each year, the site serves more than 80 countries through its customers. The site has more than 350 employees.


About Unither Pharmaceuticals

Unither Pharmaceuticals is a pharmaceutical subcontractor specializing in the development and production of single-dose liquid formulations (including eye drops, saline solutions, asthma medications in single-dose BFS, and stick-packs) for pharmaceutical companies and generic manufacturers. Currently employing more than 2,000 people in eight manufacturing plants in France, the United States, Brazil and China, Unither Pharmaceuticals has sales of €371 million in 2022.

For more information about the Unither Pharmaceuticals group, visit


Press contact:

Unither Pharmaceuticals

Tel: +33 (0)1 44 63 51 70